Phase II study of lapatinib and tegafur combination efficacy for the treatment of HER2+metastatic breast cancer.

被引：0
|
作者：
Manikhas, Alexey
Sharvashidze, Ineza O.
Kotkova, Tatjana N.
机构：
[1] City Clin Oncol Dispensary, St Petersburg, Russia
[2] State Clin Oncol Dispensary, St Petersburg, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11086
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Updated Austrian treatment algorithm in HER2+metastatic breast cancer
    Bartsch, Rupert
    Gampenrieder, Simon Peter
    Rinnerthaler, Gabriel
    Petru, Edgar
    Egle, Daniel
    Petzer, Andreas
    Balic, Marija
    Pluschnig, Ursula
    Sliwa, Thamer
    Singer, Christian
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (1-2) : 63 - 72
  • [32] Phase II trial of trastuzumab and paclitaxel or docetaxel administered every 3 weeks to patients receiving a first treatment for HER2+metastatic breast cancer.
    Stewart, JA
    Fehrenbacher, L
    Blanchard, RA
    Rodriguez, GI
    Vogel, CL
    Anavekar, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 78S - 78S
  • [33] Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+metastatic breast cancer
    Esteva, F. J.
    Franco, S.
    Hagan, M. K.
    Brewster, A.
    Williams, W.
    Florance, A. M.
    Koch, K.
    Turner, S. J.
    Ridderheim, M.
    Perez, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Comparative effectiveness of trastuzumab emtansine versus lapatinib plus capecitabine for HER2+metastatic breast cancer
    Ramagopalan, Sreeram, V
    Pisoni, Riccardo
    Zenin, Aleksandr
    Rathore, Lokendra Singh
    Ray, Joshua
    Sammon, Cormac
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (07) : 595 - 602
  • [35] Evolving HER2+Metastatic Breast Cancer Landscape
    Seidman, Andrew D.
    Bardia, Aditya
    Pegram, Mark
    Rao, Ruta
    ONCOLOGY-NEW YORK, 2021, 35 (12): : 839 - 842
  • [36] Multicenter phase 2 trial of varlitinib versus lapatinib in combination with capecitabine in patients with HER2+metastatic breast cancer (MBC) who failed prior trastuzumab therapy
    Lee, S. C.
    Chen, S-C.
    Dai, M-S.
    Lee, G. E.
    Liu, C-L.
    Chan, A.
    Chang, H-K.
    Tseng, L-M.
    Chay, W. Y.
    Chow, L. W. C.
    Peneyra, J. L.
    Rau, K-M.
    Wang, H-C.
    Guancia, A. A.
    Head, M.
    Chiu, J. W. Y.
    Robinson, B.
    Lindmark, B.
    McIntyre, N.
    Hsieh, C-Y.
    ANNALS OF ONCOLOGY, 2017, 28 : 30 - 30
  • [37] Relapsed/Refractory HER2+Metastatic Breast Cancer
    Brufsky, Adam M.
    Gadi, V. K.
    Hurvitz, Sara A.
    Iyengar, Neil M.
    ONCOLOGY-NEW YORK, 2021, 35 (04): : 215 - 219
  • [38] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
    Bayo, J
    Mayordomo, JI
    Sanchez-Rovira, P
    Perez-Carrion, R
    Illaramendi, J
    Flores, EG
    Bueno, JMG
    Vazquez, MR
    Crespo, C
    Palomo, AG
    Huelva, HJRJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [39] A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer.
    Soliman, Hatem Hussein
    Minton, Susan E.
    Ismail-Khan, Roohi
    Han, Hyo S.
    Vahanlan, Nicholas N.
    Ramsey, William Jay
    Kennedy, Eugene
    Link, Charles J.
    Sullivan, Daniel
    Antonia, Scott Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
    Chew, Helen Kent
    Schwartzberg, Lee
    Badarinath, Suprith
    Rubin, Peter
    Shumaker, Grace
    Daugherty, James
    DeSilvio, Michelle
    Mahoney, Janine
    SPRINGERPLUS, 2014, 3
12345